Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anaphylactoid reactions associated with bisantrene infusions.

Literature DB >> 6678858

Anaphylactoid reactions associated with bisantrene infusions.

J W Myers, D D Von Hoff, J G Kuhn, C K Osborne, J F Sandbach, R Pocelinko.

Abstract

Nine of ninety-three patients receiving Bisantrene on an every three week schedule developed an anaphylactoid reaction with a variety of symptoms. Most reactions occurred in patients who had multiple exposures to Bisantrene. Investigators utilizing Bisantrene in ongoing clinical trials should be aware of this life threatening toxicity.

Entities: Chemical Disease Species

Mesh：

Substances：
Anthracenes
bisantrene

Year: 1983 PMID： 6678858 DOI： 10.1007/bf00180195

Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850

9 in total

1. Hypersensitivity reaction to cancer chemotherapy.

Authors: R B Weiss
Journal: Semin Oncol Date: 1982-03 Impact factor: 4.929

2. Chronic urticarial reactions caused by doxorubicin-containing regimens.

Authors: A K Hatfield; L Harder; R T Abderhalden
Journal: Cancer Treat Rep Date: 1981 Mar-Apr

3. Phase II evaluation of bisantrene in patients with renal cell carcinoma.

Authors: J W Myers; D D Von Hoff; C A Coltman; J G Kuhn; D Van Echo; S Rivkin; R Pocelinko
Journal: Cancer Treat Rep Date: 1982-10

4. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).

Authors: B S Yap; H Y Yap; G R Blumenschein; A Y Bedikian; R Pocelinko; G P Bodey
Journal: Cancer Treat Rep Date: 1982-07

5. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog.

Authors: E H Herman; R S Young
Journal: Cancer Treat Rep Date: 1979 Nov-Dec

6. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.

Authors: R J Spiegel; R H Blum; M Levin; C A Pinto; J C Wernz; J L Speyer; K S Hoffman; F M Muggia
Journal: Cancer Res Date: 1982-01 Impact factor: 12.701

7. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.

Authors: J Bickers; R Benjamin; H Wilson; H Eyre; J Hewlett; K McCredie
Journal: Cancer Treat Rep Date: 1981 May-Jun

8. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.

Authors: D S Alberts; C Mackel; R Pocelinko; S E Salmon
Journal: Cancer Res Date: 1982-03 Impact factor: 12.701

9. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).

Authors: D D Von Hoff; J W Myers; J Kuhn; J F Sandbach; R Pocelinko; G Clark; C A Coltman
Journal: Cancer Res Date: 1981-08 Impact factor: 12.701

9 in total

4 in total

1. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).

Authors: J D Cowan; C K Osborne; J A Neidhart; D D Von Hoff; J J Constanzi; C B Vaughn
Journal: Invest New Drugs Date: 1985 Impact factor: 3.850